St Vincent's Hospital Sydney
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia30 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-10-09 | NCT07177352 | |
| A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, digestive system disorder, digestive system neoplasm, gastric neoplasm, lethal congenital contracture syndrome 2, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, stomach disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07070232 | |
| A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT07567846 | |
| A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT07100106 | |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 | 2026-10-06 | NCT05800665 | |
| A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | Familial Primary Pulmonary Hypertension, Skin and Connective Tissue Diseases, cardiovascular disorder, connective tissue disorder, hypertensive disorder, lung disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorder, vascular disorder | Enrolling by invitation | Phase 3 | 2026-10-06 | NCT03683186 | |
| A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases | interstitial lung disease, lung disorder, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-02 | NCT06806592 | |
| Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC | mCRPC | Active, not recruiting | Phase 3 | 2026-09-29 | NCT03395197 | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s) | neoplasm | Recruiting | Phase 1 | 2026-09-28 | NCT06884618 | |
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | Hemic and Lymphatic Diseases, Lymphadenopathy, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, peripheral T-cell lymphoma, not otherwise specified | Recruiting | Phase 3 | 2026-09-25 | NCT06561048 | |
| A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors | Solid Tumor | Recruiting | Phase 1 | 2026-09-23 | NCT06619587 | |
| CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | Recruiting | Phase 3 | 2026-09-22 | NCT07207811 | |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, male breast carcinoma, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-09-15 | NCT06492616 | |
| A Phase I Study of CS5007 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 | 2026-08-14 | NCT07622524 | |
| A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 1 | 2026-08-13 | NCT03332797 | |
| Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy | Egg Hypersensitivity, Hypersensitivity, Immediate, Milk Hypersensitivity, Nut and Peanut Hypersensitivity, Peanut Hypersensitivity, food allergy, immune system disorder | Recruiting | Phase 2 | 2026-07-28 | NCT07220811 | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Locally Advanced Solid Tumors; Metastatic Solid Tumors; Recurrent Solid Tumors | Active, not recruiting | Phase 1 | 2026-07-28 | NCT06031441 | |
| Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | Digestive System Diseases, Digestive System Neoplasms, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, astrocytoma (excluding glioblastoma), breast disorder, breast neoplasm, carcinoma, central nervous system cancer, cholangiocarcinoma, chondrosarcoma, colonic disorder, colonic neoplasm, colorectal neoplasm, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, glioblastoma, glioma, intestinal disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, neoplasm, nervous system disorder, neuroendocrine neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate disorder, sarcoma, skin disorder, skin neoplasm, thyroid gland disorder, thyroid tumor | Active, not recruiting | Phase 1 | 2026-07-22 | NCT04521686 | |
| A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age | Alzheimer's Disease Dementia; Mild Cognitive Impairment Due to Alzheimer's Disease | Active, not recruiting | Phase 2 | 2026-06-30 | NCT05399888 | |
| A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast cancer, breast disorder, breast neoplasm, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, skin disorder, uterine disorder | Active, not recruiting | Phase 1 | 2026-06-22 | NCT04188548 | |
| Staphylococcus Aureus Network Adaptive Platform Trial | Bacterial Infections and Mycoses, Infections, bacterial infectious disease, gram-positive bacterial infections, staphylococcal infection | Recruiting | Phase 4 | 2026-05-06 | NCT05137119 | |
| A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | Locally Advanced Unresectable or Metastatic Solid Tumors | Recruiting | Phase 1 | 2026-05-04 | NCT05458219 | |
| SODium BICarbonate for Metabolic Acidosis in the ICU | Acid-Base Imbalance, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, acidosis disorder, metabolic acidosis, metabolic disease | Active, not recruiting | Phase 3 | 2026-03-27 | NCT05697770 | |
| Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2025-10-03 | NCT05840211 | |
| A Study of VRN101099 in Patients With HER2-Positive Solid Tumors | HER2-positive Solid Tumors | Recruiting | Phase 1 | 2025-08-28 | NCT06806982 |